Display options
Share it on

Dermatol Ther (Heidelb). 2012 Dec;2(1):15. doi: 10.1007/s13555-012-0015-5. Epub 2012 Oct 09.

Inverse psoriasis involving genital skin folds: successful therapy with dapsone.

Dermatology and therapy

Antonio Guglielmetti, Rodrigo Conlledo, Juliana Bedoya, Francisco Ianiszewski, Julio Correa

Affiliations

  1. Department of Dermatology, University of Valparaíso, Hontaneda 2653 Valparaíso, Chile.

PMID: 23205337 PMCID: PMC3510394 DOI: 10.1007/s13555-012-0015-5

Abstract

INTRODUCTION: Inverse psoriasis is a rare form of psoriasis that affects between 3% and 7% of the patients with psoriasis. It can comprise genital skin folds as part of genital psoriasis, and it is one of the most commonly seen dermatoses of this area. There are few evidence-based studies about the treatment of intertriginous psoriasis involving genital skin folds.

CASE PRESENTATION: The authors present a 42-year-old female patient with erythematous plaques in the vulva, groin, and perianal region. The patient had previously received a broad range of topical and systemic therapies that had to be discontinued due to ineffectiveness or side effects. She was treated with 100 mg dapsone daily for 10 months, showing a significant improvement of her cutaneous and mucous lesions. Complete clearance of psoriatic lesions was observed after 4 weeks of treatment. She has remained in remission for up to 2 years, using only topical therapy with tacrolimus 0.1% and calcipotriol.

DISCUSSION: Genital psoriasis is a skin disease that causes great discomfort. It is important to include examination of the genital region and to adopt this conduct in daily clinical practice. Research in this field is still poor, making no discrimination between flexural and genital psoriasis, and is based on case series and expert opinion; therefore, empirical recommendations for the treatment of genital psoriasis remain. Dapsone has been shown to be an effective and convenient alternative for the treatment of inverse psoriasis in genital skin folds, which can provide effective control of the disease. Further studies are required to determine the efficacy and safety of current therapies, and to decide whether dapsone therapy should be considered in the management of this form of psoriasis when topical and other systemic agents are not effective.

References

  1. J Eur Acad Dermatol Venereol. 2005 Nov;19 Suppl 3:2-6 - PubMed
  2. J Dermatol. 2001 Jun;28(6):316-9 - PubMed
  3. Arch Dermatol. 2006 Sep;142(9):1138-43 - PubMed
  4. Clin Exp Dermatol. 2004 Jul;29(4):354-6 - PubMed
  5. Arch Dermatol. 1968 Sep;98(3):248-59 - PubMed
  6. J Am Acad Dermatol. 2009 Jan;60(1):120-4 - PubMed
  7. Arch Dermatol. 1960 Mar;81:400-4 - PubMed
  8. MMW Fortschr Med. 2002 Mar 21;144(12):30-2, 34-5 - PubMed
  9. Eur J Dermatol. 2008 Nov-Dec;18(6):671-6 - PubMed
  10. Cutis. 1992 Oct;50(4):263-6 - PubMed
  11. JAMA. 2003 Aug 27;290(8):1001-5 - PubMed
  12. Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii30-6 - PubMed
  13. Br J Obstet Gynaecol. 1995 Oct;102(10):773-9 - PubMed
  14. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):388-9 - PubMed
  15. Acta Derm Venereol. 1964;44(3):191-207 - PubMed
  16. J Am Acad Dermatol. 1993 Dec;29(6):1048-9 - PubMed
  17. Dermatol Surg. 1996 Sep;22(9):781-6 - PubMed
  18. Br J Dermatol. 1973 Feb;88(2):183-5 - PubMed
  19. Dermatology. 2000;200(4):292-8 - PubMed
  20. Urol Clin North Am. 1992 Feb;19(1):111-21 - PubMed
  21. Aust Fam Physician. 1999 Apr;28(4):385-6 - PubMed
  22. Clin Exp Dermatol. 2001 Jun;26(4):314-20 - PubMed
  23. Australas J Dermatol. 2001 Nov;42(4):225-34; quiz, 235-6 - PubMed
  24. Pediatr Dermatol. 2005 May-Jun;22(3):250-3 - PubMed
  25. Dermatol Online J. 2008 Jan 15;14(1):1 - PubMed
  26. J Eur Acad Dermatol Venereol. 2001 Jan;15(1):16-7 - PubMed
  27. Mod Pathol. 1997 May;10(5):401-8 - PubMed
  28. J Am Acad Dermatol. 2009 Sep;61(3):451-85 - PubMed
  29. Br J Obstet Gynaecol. 1995 Oct;102(10):780-6 - PubMed
  30. Clin Dermatol. 2008 Sep-Oct;26(5):546-53 - PubMed
  31. BJU Int. 2002 Sep;90(5):498-506 - PubMed
  32. Int J Dermatol. 1996 Mar;35(3):202-4 - PubMed
  33. Proc R Soc Med. 1977 Apr;70(4):286-7 - PubMed
  34. J Pediatr Adolesc Gynecol. 2005 Feb;18(1):43-6 - PubMed
  35. Pediatr Dermatol. 2000 Jan-Feb;17(1):1-6 - PubMed
  36. Clin Dermatol. 2006 Sep-Oct;24(5):438-47 - PubMed
  37. Br J Dermatol. 1977 Jul;97 Suppl 15:64-6 - PubMed
  38. Postgrad Med. 2000 Sep 15;108(4):89-91, 95-6 - PubMed
  39. Pediatr Dermatol. 1998 Mar-Apr;15(2):144-6 - PubMed
  40. An Bras Dermatol. 2010 Nov-Dec;85(6):899-902 - PubMed
  41. Acta Derm Venereol. 2011 Jan;91(1):5-11 - PubMed
  42. Pediatr Dermatol. 2001 May-Jun;18(3):188-98 - PubMed
  43. Aust Fam Physician. 2004 Jul;33(7):505-10 - PubMed
  44. Eur J Dermatol. 2005 May-Jun;15(3):176-8 - PubMed
  45. Cutis. 1993 Jan;51(1):29-32 - PubMed
  46. Br J Dermatol. 2005 Nov;153(5):960-6 - PubMed
  47. J Am Acad Dermatol. 2002 Jun;46(6):900-6 - PubMed
  48. Dermatologica. 1974;148(1):1-18 - PubMed
  49. J Am Acad Dermatol. 1996 Jan;34(1):1-25; quiz 26-8 - PubMed
  50. Reumatismo. 2007;59 Suppl 1:56-60 - PubMed
  51. Dermatology. 2005;210(2):150-6 - PubMed

Publication Types